ACRUX LIMITED - Announcements

0.00%

1.8¢

Market Cap $7.366M

Healthcare Drug Manufacturers - Specialty & Generic

Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is... Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

ACR	Axiron Generic Launched In The United States	PRICE SENSITIVE	06/07/17	332.87KB	Share
ACR	Institution of IPR Proceeding Against Key Jublia Patent	PRICE SENSITIVE	02/05/17	428.23KB	Share
ACR	Axiron Net Sales Quarter to 31 March 2017	PRICE SENSITIVE	26/04/17	338.15KB	Share
ACR	S&P DJ Indices Announces March Quarterly Rebalance	PRICE SENSITIVE	10/03/17	177.37KB	Share
ACR	Appendix 4D and Half Year Report to 31 December 2016	PRICE SENSITIVE	17/02/17	1.59MB	Share
ACR	Axiron Net Sales, Quarter to December2016	PRICE SENSITIVE	01/02/17	336.85KB	Share
ACR	IPR Petition Filed Against Key Jublia Patent-ACR.AX	PRICE SENSITIVE	03/11/16	431.74KB	Share
ACR	IPR Petition Filed Against Key Jublia Patent	PRICE SENSITIVE	03/11/16	431.74KB	Share
ACR	NEW INTELLECTUAL PROPERTY APPLICATION FOR ONYCHOMYCOSIS-ACR.AX	PRICE SENSITIVE	02/11/16	256.15KB	Share
ACR	Axiron Net Sales, Quarter to September 2016-ACR.AX	PRICE SENSITIVE	26/10/16	253.95KB	Share
ACR	Appendix 4E-ACR.AX	PRICE SENSITIVE	28/08/16	223.19KB	Share
ACR	Acrux announces 2016 financial results-ACR.AX	PRICE SENSITIVE	28/08/16	383.41KB	Share
ACR	Acrux announces 2016 financial results-ACR.AX	PRICE SENSITIVE	25/08/16	383.41KB	Share
ACR	Appendix 4E-ACR.AX	PRICE SENSITIVE	25/08/16	223.19KB	Share
ACR	Acrux and Eli Lilly to appeal patent ruling on Axiron-ACR.AX	PRICE SENSITIVE	24/08/16	366.43KB	Share
ACR	Acrux announces court ruling on Axiron patent families-ACR.AX	PRICE SENSITIVE	23/08/16	329.42KB	Share
ACR	Axiron Net Sales, quarter to June 2016-ACR.AX	PRICE SENSITIVE	27/07/16	592.1KB	Share
ACR	Acrux generic strategy and Axiron patent litigation update-ACR.AX	PRICE SENSITIVE	30/06/16	351.92KB	Share
ACR	Axiron Net Sales, quarter to March 2016-ACR.AX	PRICE SENSITIVE	27/04/16	499KB	Share
ACR	Acrux Appendix 4D - December 2015	PRICE SENSITIVE	25/02/16	173.96KB	Share
ACR	Axiron Net Sales, quarter to 31 December 2015	PRICE SENSITIVE	29/01/16	423.24KB	Share
ACR	Axiron Net Sales, quarter to September 2015	PRICE SENSITIVE	23/10/15	357.36KB	Share
ACR	European approvals and milestone payments for Lenzetto	PRICE SENSITIVE	07/09/15	124.8KB	Share
ACR	Acrux announces 2015 Financial Result and Dividend	PRICE SENSITIVE	13/08/15	1.98MB	Share
ACR	Axiron Net Sales, quarter to June 2015	PRICE SENSITIVE	24/07/15	407.51KB	Share
ACR	Lilly and Acrux file lawsuit against Lupin	PRICE SENSITIVE	07/07/15	356.15KB	Share
ACR	Axiron Net Sales, quarter to March 2015	PRICE SENSITIVE	24/04/15	103.98KB	Share
ACR	Appendix 4D - 31 December 2014	PRICE SENSITIVE	26/02/15	163.9KB	Share
ACR	Axiron Net Sales, quarter to 31 December 2014	PRICE SENSITIVE	02/02/15	231.85KB	Share
ACR	Lilly and Acrux file lawsuit against Amneal	PRICE SENSITIVE	11/12/14	110.06KB	Share
ACR	Axiron Net Sales, quarter to 30 September 2014	PRICE SENSITIVE	24/10/14	106.54KB	Share
ACR	Response to ASX Price Query	PRICE SENSITIVE	18/09/14	285.25KB	Share
ACR	Trading Halt	PRICE SENSITIVE	18/09/14	29.93KB	Share
ACR	Hexima Collaboration Update	PRICE SENSITIVE	21/08/14	20.54KB	Share
ACR	Appendix 4E and Financial Report to 30 June 2014	PRICE SENSITIVE	21/08/14	926.32KB	Share
ACR	Marketing Approval Granted for Estradiol Spray South Africa	PRICE SENSITIVE	20/08/14	106.93KB	Share
ACR	Axiron Net Sales for the Quarter to 30 June 2014	PRICE SENSITIVE	25/07/14	20.62KB	Share
ACR	Acrux Appoints New CEO	PRICE SENSITIVE	25/07/14	21.97KB	Share
ACR	Response to ASX price query	PRICE SENSITIVE	08/07/14	533.17KB	Share
ACR	Axiron Net Sales for the Quarter to 31 March 2014	PRICE SENSITIVE	28/04/14	21.38KB	Share
ACR	Response to ASX Price Query	PRICE SENSITIVE	07/03/14	1.15MB	Share
ACR	Half Yearly Report and Accounts	PRICE SENSITIVE	20/02/14	1.76MB	Share
ACR	Response to ASX Price Query	PRICE SENSITIVE	05/02/14	159.67KB	Share
ACR	Trading Halt	PRICE SENSITIVE	04/02/14	65.33KB	Share
ACR	Axiron Net Sales for the Quarter to 31 December 2013	PRICE SENSITIVE	31/01/14	65.94KB	Share
ACR	Axiron Launched in Brazil	PRICE SENSITIVE	28/11/13	105.49KB	Share
ACR	Lilly and Acrux file lawsuit against Actavis	PRICE SENSITIVE	13/11/13	124.49KB	Share
ACR	Axiron net sales, quarter to 30 September 2013	PRICE SENSITIVE	24/10/13	107.55KB	Share
ACR	Acrux Announces First European Approval for AXIRON	PRICE SENSITIVE	07/10/13	157.08KB	Share
ACR	Appendix 4E and Financial Report to 30 June 2013	PRICE SENSITIVE	27/08/13	2.63MB	Share
ACR	Axiron net sales, quarter to 30 June 2013	PRICE SENSITIVE	25/07/13	19.91KB	Share
ACR	Axiron launched in Canada	PRICE SENSITIVE	28/06/13	15.54KB	Share
ACR	Richter to commercialise estradiol spray in ex-US markets	PRICE SENSITIVE	27/06/13	37.94KB	Share
ACR	Axiron net sales, quarter to 31 March 2013	PRICE SENSITIVE	26/04/13	19.34KB	Share
ACR	Acrux provides half-year update	PRICE SENSITIVE	18/02/13	62.78KB	Share
ACR	Half Yearly Report and Accounts	PRICE SENSITIVE	18/02/13	314.58KB	Share
ACR	Allowance of underarm administration patent in United States	PRICE SENSITIVE	12/02/13	20KB	Share
ACR	2012 AGM Presentation	PRICE SENSITIVE	22/11/12	203.11KB	Share
ACR	Dividend, June 2012 results and Axiron update	PRICE SENSITIVE	23/08/12	31.39KB	Share
ACR	Appendix 4E and Financial Report for 30 June 2012	PRICE SENSITIVE	23/08/12	1.69MB	Share
ACR	Recuvyra approved by FDA	PRICE SENSITIVE	26/06/12	16.55KB	Share
ACR	Patent application update	PRICE SENSITIVE	21/06/12	19.77KB	Share
ACR	Axiron Marketing Authorisation Granted in Australia	PRICE SENSITIVE	25/05/12	21.48KB	Share
ACR	Axiron market update	PRICE SENSITIVE	26/04/12	22.06KB	Share
ACR	Axiron marketing authorisation granted in Canada	PRICE SENSITIVE	12/04/12	19.93KB	Share
ACR	Acrux announces board changes	PRICE SENSITIVE	22/02/12	40.24KB	Share
ACR	Half Yearly Report and Accounts	PRICE SENSITIVE	22/02/12	200.82KB	Share
ACR	Notice of Allowance in USA for Axiron applicator patent	PRICE SENSITIVE	31/01/12	20.23KB	Share
ACR	Marketing approval granted for Ellavie in Switzerland	PRICE SENSITIVE	30/01/12	21.77KB	Share
ACR	Orion manufacturing facility update	PRICE SENSITIVE	01/12/11	19.89KB	Share
ACR	Orion manufacturing facility, Finland	PRICE SENSITIVE	24/11/11	19.89KB	Share
ACR	2026 patent for Axiron granted by Australian patent office	PRICE SENSITIVE	03/11/11	21.74KB	Share
ACR	Marketing authorisation for Recuvyra granted in Europe	PRICE SENSITIVE	13/10/11	17.32KB	Share
ACR +ALD ALK API ASZ BKY BSL CCP CNP CPB CUS DCG K2P FML ETM GMG HIL HUN IDL IFN ILU MCP MCR MEO MTU NDO OST PPT SRS IMM QUB RHG SFH SPL SSN STB TGA TGS ZSP	SandP Indices Announces September Quarterly Rebalance	PRICE SENSITIVE	09/09/11	62.33KB	Share
ACR	Appendix 4E and Financial Report for the year ended 30 June	PRICE SENSITIVE	23/08/11	3.55MB	Share
ACR	Appendix 4C - Quarterly Cash Flow Report	PRICE SENSITIVE	29/07/11	90.03KB	Share
ACR	Eli Lilly provides feedback on initial uptake of Axiron	PRICE SENSITIVE	01/07/11	517.82KB	Share
ACR	Acrux receives marketing approval for Ellavie in Sweden	PRICE SENSITIVE	27/05/11	125.04KB	Share
ACR	Positive European opinion for first animal health product	PRICE SENSITIVE	10/05/11	98.91KB	Share
ACR	Appendix 4C - Quarterly Cash Flow Report	PRICE SENSITIVE	29/04/11	89.96KB	Share
ACR	Axiron Launched by Eli Lilly in the United States	PRICE SENSITIVE	31/03/11	52.55KB	Share
ACR	Acrux Declares First Dividend of 60 cents per share	PRICE SENSITIVE	24/03/11	46.13KB	Share
ACR	Half Year Accounts and Appendix 4D	PRICE SENSITIVE	24/02/11	272.94KB	Share
ACR	Appendix 4C - Quarterly Cash Flow Report	PRICE SENSITIVE	31/01/11	89.75KB	Share
ACR	2010 AGM Presentations	PRICE SENSITIVE	30/11/10	2.09MB	Share
ACR	FDA Approval for AXIRON	PRICE SENSITIVE	24/11/10	82.21KB	Share
ACR	Market Update	PRICE SENSITIVE	24/11/10	49.12KB	Share
ACR	Trading Halt	PRICE SENSITIVE	24/11/10	41.63KB	Share
ACR	Response to ASX Price Query	PRICE SENSITIVE	01/11/10	95.12KB	Share
ACR	Appendix 4C - Quarterly Cash Flow Report	PRICE SENSITIVE	29/10/10	89.74KB	Share
ACR	Appendix 4E and 30 June 2010 Financial Report	PRICE SENSITIVE	24/08/10	241.25KB	Share
ACR	Update on Acrux female health products	PRICE SENSITIVE	10/08/10	26.48KB	Share
ACR	Appendix 4C - Quarterly Cash Flow Report	PRICE SENSITIVE	30/07/10	90.21KB	Share
ACR	Settlement Agreement Transferring Luramist Assets to Acrux	PRICE SENSITIVE	11/05/10	20.59KB	Share
ACR	Appendix 4C - Quarterly Cash Flow Report	PRICE SENSITIVE	30/04/10	89.51KB	Share
ACR	New Drug Application for AXIRON accepted for review by FDA	PRICE SENSITIVE	15/04/10	19.95KB	Share
ACR	Acrux to regain rights to testosterone spray from Vivus	PRICE SENSITIVE	01/04/10	20.34KB	Share
ACR	Acrux and Eli Lilly sign global licensing deal for AXIRON	PRICE SENSITIVE	16/03/10	31.23KB	Share
ACR	Market Update - A New Era For Acrux	PRICE SENSITIVE	16/03/10	62.02KB	Share
ACR	Trading Halt	PRICE SENSITIVE	15/03/10	41.78KB	Share

ACR Axiron Generic Launched In The United States
06/07/17	PRICE SENSITIVE	332.87KB	Share
ACR Institution of IPR Proceeding Against Key Jublia Patent
02/05/17	PRICE SENSITIVE	428.23KB	Share
ACR Axiron Net Sales Quarter to 31 March 2017
26/04/17	PRICE SENSITIVE	338.15KB	Share
ACR S&P DJ Indices Announces March Quarterly Rebalance
10/03/17	PRICE SENSITIVE	177.37KB	Share
ACR Appendix 4D and Half Year Report to 31 December 2016
17/02/17	PRICE SENSITIVE	1.59MB	Share
ACR Axiron Net Sales, Quarter to December2016
01/02/17	PRICE SENSITIVE	336.85KB	Share
ACR IPR Petition Filed Against Key Jublia Patent-ACR.AX
03/11/16	PRICE SENSITIVE	431.74KB	Share
ACR IPR Petition Filed Against Key Jublia Patent
03/11/16	PRICE SENSITIVE	431.74KB	Share
ACR NEW INTELLECTUAL PROPERTY APPLICATION FOR ONYCHOMYCOSIS-ACR.AX
02/11/16	PRICE SENSITIVE	256.15KB	Share
ACR Axiron Net Sales, Quarter to September 2016-ACR.AX
26/10/16	PRICE SENSITIVE	253.95KB	Share
ACR Appendix 4E-ACR.AX
28/08/16	PRICE SENSITIVE	223.19KB	Share
ACR Acrux announces 2016 financial results-ACR.AX
28/08/16	PRICE SENSITIVE	383.41KB	Share
ACR Acrux announces 2016 financial results-ACR.AX
25/08/16	PRICE SENSITIVE	383.41KB	Share
ACR Appendix 4E-ACR.AX
25/08/16	PRICE SENSITIVE	223.19KB	Share
ACR Acrux and Eli Lilly to appeal patent ruling on Axiron-ACR.AX
24/08/16	PRICE SENSITIVE	366.43KB	Share
ACR Acrux announces court ruling on Axiron patent families-ACR.AX
23/08/16	PRICE SENSITIVE	329.42KB	Share
ACR Axiron Net Sales, quarter to June 2016-ACR.AX
27/07/16	PRICE SENSITIVE	592.1KB	Share
ACR Acrux generic strategy and Axiron patent litigation update-ACR.AX
30/06/16	PRICE SENSITIVE	351.92KB	Share
ACR Axiron Net Sales, quarter to March 2016-ACR.AX
27/04/16	PRICE SENSITIVE	499KB	Share
ACR Acrux Appendix 4D - December 2015
25/02/16	PRICE SENSITIVE	173.96KB	Share
ACR Axiron Net Sales, quarter to 31 December 2015
29/01/16	PRICE SENSITIVE	423.24KB	Share
ACR Axiron Net Sales, quarter to September 2015
23/10/15	PRICE SENSITIVE	357.36KB	Share
ACR European approvals and milestone payments for Lenzetto
07/09/15	PRICE SENSITIVE	124.8KB	Share
ACR Acrux announces 2015 Financial Result and Dividend
13/08/15	PRICE SENSITIVE	1.98MB	Share
ACR Axiron Net Sales, quarter to June 2015
24/07/15	PRICE SENSITIVE	407.51KB	Share
ACR Lilly and Acrux file lawsuit against Lupin
07/07/15	PRICE SENSITIVE	356.15KB	Share
ACR Axiron Net Sales, quarter to March 2015
24/04/15	PRICE SENSITIVE	103.98KB	Share
ACR Appendix 4D - 31 December 2014
26/02/15	PRICE SENSITIVE	163.9KB	Share
ACR Axiron Net Sales, quarter to 31 December 2014
02/02/15	PRICE SENSITIVE	231.85KB	Share
ACR Lilly and Acrux file lawsuit against Amneal
11/12/14	PRICE SENSITIVE	110.06KB	Share
ACR Axiron Net Sales, quarter to 30 September 2014
24/10/14	PRICE SENSITIVE	106.54KB	Share
ACR Response to ASX Price Query
18/09/14	PRICE SENSITIVE	285.25KB	Share
ACR Trading Halt
18/09/14	PRICE SENSITIVE	29.93KB	Share
ACR Hexima Collaboration Update
21/08/14	PRICE SENSITIVE	20.54KB	Share
ACR Appendix 4E and Financial Report to 30 June 2014
21/08/14	PRICE SENSITIVE	926.32KB	Share
ACR Marketing Approval Granted for Estradiol Spray South Africa
20/08/14	PRICE SENSITIVE	106.93KB	Share
ACR Axiron Net Sales for the Quarter to 30 June 2014
25/07/14	PRICE SENSITIVE	20.62KB	Share
ACR Acrux Appoints New CEO
25/07/14	PRICE SENSITIVE	21.97KB	Share
ACR Response to ASX price query
08/07/14	PRICE SENSITIVE	533.17KB	Share
ACR Axiron Net Sales for the Quarter to 31 March 2014
28/04/14	PRICE SENSITIVE	21.38KB	Share
ACR Response to ASX Price Query
07/03/14	PRICE SENSITIVE	1.15MB	Share
ACR Half Yearly Report and Accounts
20/02/14	PRICE SENSITIVE	1.76MB	Share
ACR Response to ASX Price Query
05/02/14	PRICE SENSITIVE	159.67KB	Share
ACR Trading Halt
04/02/14	PRICE SENSITIVE	65.33KB	Share
ACR Axiron Net Sales for the Quarter to 31 December 2013
31/01/14	PRICE SENSITIVE	65.94KB	Share
ACR Axiron Launched in Brazil
28/11/13	PRICE SENSITIVE	105.49KB	Share
ACR Lilly and Acrux file lawsuit against Actavis
13/11/13	PRICE SENSITIVE	124.49KB	Share
ACR Axiron net sales, quarter to 30 September 2013
24/10/13	PRICE SENSITIVE	107.55KB	Share
ACR Acrux Announces First European Approval for AXIRON
07/10/13	PRICE SENSITIVE	157.08KB	Share
ACR Appendix 4E and Financial Report to 30 June 2013
27/08/13	PRICE SENSITIVE	2.63MB	Share
ACR Axiron net sales, quarter to 30 June 2013
25/07/13	PRICE SENSITIVE	19.91KB	Share
ACR Axiron launched in Canada
28/06/13	PRICE SENSITIVE	15.54KB	Share
ACR Richter to commercialise estradiol spray in ex-US markets
27/06/13	PRICE SENSITIVE	37.94KB	Share
ACR Axiron net sales, quarter to 31 March 2013
26/04/13	PRICE SENSITIVE	19.34KB	Share
ACR Acrux provides half-year update
18/02/13	PRICE SENSITIVE	62.78KB	Share
ACR Half Yearly Report and Accounts
18/02/13	PRICE SENSITIVE	314.58KB	Share
ACR Allowance of underarm administration patent in United States
12/02/13	PRICE SENSITIVE	20KB	Share
ACR 2012 AGM Presentation
22/11/12	PRICE SENSITIVE	203.11KB	Share
ACR Dividend, June 2012 results and Axiron update
23/08/12	PRICE SENSITIVE	31.39KB	Share
ACR Appendix 4E and Financial Report for 30 June 2012
23/08/12	PRICE SENSITIVE	1.69MB	Share
ACR Recuvyra approved by FDA
26/06/12	PRICE SENSITIVE	16.55KB	Share
ACR Patent application update
21/06/12	PRICE SENSITIVE	19.77KB	Share
ACR Axiron Marketing Authorisation Granted in Australia
25/05/12	PRICE SENSITIVE	21.48KB	Share
ACR Axiron market update
26/04/12	PRICE SENSITIVE	22.06KB	Share
ACR Axiron marketing authorisation granted in Canada
12/04/12	PRICE SENSITIVE	19.93KB	Share
ACR Acrux announces board changes
22/02/12	PRICE SENSITIVE	40.24KB	Share
ACR Half Yearly Report and Accounts
22/02/12	PRICE SENSITIVE	200.82KB	Share
ACR Notice of Allowance in USA for Axiron applicator patent
31/01/12	PRICE SENSITIVE	20.23KB	Share
ACR Marketing approval granted for Ellavie in Switzerland
30/01/12	PRICE SENSITIVE	21.77KB	Share
ACR Orion manufacturing facility update
01/12/11	PRICE SENSITIVE	19.89KB	Share
ACR Orion manufacturing facility, Finland
24/11/11	PRICE SENSITIVE	19.89KB	Share
ACR 2026 patent for Axiron granted by Australian patent office
03/11/11	PRICE SENSITIVE	21.74KB	Share
ACR Marketing authorisation for Recuvyra granted in Europe
13/10/11	PRICE SENSITIVE	17.32KB	Share
ACR +ALD ALK API ASZ BKY BSL CCP CNP CPB CUS DCG K2P FML ETM GMG HIL HUN IDL IFN ILU MCP MCR MEO MTU NDO OST PPT SRS IMM QUB RHG SFH SPL SSN STB TGA TGS ZSPSandP Indices Announces September Quarterly Rebalance
09/09/11	PRICE SENSITIVE	62.33KB	Share
ACR Appendix 4E and Financial Report for the year ended 30 June
23/08/11	PRICE SENSITIVE	3.55MB	Share
ACR Appendix 4C - Quarterly Cash Flow Report
29/07/11	PRICE SENSITIVE	90.03KB	Share
ACR Eli Lilly provides feedback on initial uptake of Axiron
01/07/11	PRICE SENSITIVE	517.82KB	Share
ACR Acrux receives marketing approval for Ellavie in Sweden
27/05/11	PRICE SENSITIVE	125.04KB	Share
ACR Positive European opinion for first animal health product
10/05/11	PRICE SENSITIVE	98.91KB	Share
ACR Appendix 4C - Quarterly Cash Flow Report
29/04/11	PRICE SENSITIVE	89.96KB	Share
ACR Axiron Launched by Eli Lilly in the United States
31/03/11	PRICE SENSITIVE	52.55KB	Share
ACR Acrux Declares First Dividend of 60 cents per share
24/03/11	PRICE SENSITIVE	46.13KB	Share
ACR Half Year Accounts and Appendix 4D
24/02/11	PRICE SENSITIVE	272.94KB	Share
ACR Appendix 4C - Quarterly Cash Flow Report
31/01/11	PRICE SENSITIVE	89.75KB	Share
ACR 2010 AGM Presentations
30/11/10	PRICE SENSITIVE	2.09MB	Share
ACR FDA Approval for AXIRON
24/11/10	PRICE SENSITIVE	82.21KB	Share
ACR Market Update
24/11/10	PRICE SENSITIVE	49.12KB	Share
ACR Trading Halt
24/11/10	PRICE SENSITIVE	41.63KB	Share
ACR Response to ASX Price Query
01/11/10	PRICE SENSITIVE	95.12KB	Share
ACR Appendix 4C - Quarterly Cash Flow Report
29/10/10	PRICE SENSITIVE	89.74KB	Share
ACR Appendix 4E and 30 June 2010 Financial Report
24/08/10	PRICE SENSITIVE	241.25KB	Share
ACR Update on Acrux female health products
10/08/10	PRICE SENSITIVE	26.48KB	Share
ACR Appendix 4C - Quarterly Cash Flow Report
30/07/10	PRICE SENSITIVE	90.21KB	Share
ACR Settlement Agreement Transferring Luramist Assets to Acrux
11/05/10	PRICE SENSITIVE	20.59KB	Share
ACR Appendix 4C - Quarterly Cash Flow Report
30/04/10	PRICE SENSITIVE	89.51KB	Share
ACR New Drug Application for AXIRON accepted for review by FDA
15/04/10	PRICE SENSITIVE	19.95KB	Share
ACR Acrux to regain rights to testosterone spray from Vivus
01/04/10	PRICE SENSITIVE	20.34KB	Share
ACR Acrux and Eli Lilly sign global licensing deal for AXIRON
16/03/10	PRICE SENSITIVE	31.23KB	Share
ACR Market Update - A New Era For Acrux
16/03/10	PRICE SENSITIVE	62.02KB	Share
ACR Trading Halt
15/03/10	PRICE SENSITIVE	41.78KB	Share

REFRESH

First 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.8¢		Change 0.000(0.00%)		Mkt cap ! $7.366M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
5	883823	1.7¢

Sellers (Offers)

Price($)	Vol.	No.
1.8¢	500697	1

View Market Depth

No.	Vol.	Price($)
5	883823	0.017
10	962673	0.016
6	1361882	0.015
2	140000	0.014
3	486850	0.013

Price($)	Vol.	No.
0.018	500697	1
0.020	56617	4
0.021	111922	1
0.022	168642	2
0.023	381179	1

Last trade - 16.21pm 30/07/2025 (20 minute delay)

ACR (ASX) Chart

Day chart unavailable

ACRUX LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available